
    
      This is a phase 1, open-label, multicenter, single-dose, single-period, sequential study with
      the primary objective of determining the effect of moderate and mild hepatic impairment on
      the PK of surufatinib. The secondary objective is to evaluate the safety in subjects with
      moderate and mild (if enrolled) hepatic impairment and subjects with normal hepatic function.
    
  